JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy

Details
By J. Smith
J. Smith
Disclaimer
Last Updated: 27 April 2025
Hits: 645
  • Medical Disclaimer
  • Health Information
  • Non-Medical Advice
  • Educational Content
  • Patient Resources

Disclaimer

General Terms

This web site is provided for educational and informational purposes only and is not medical advice or a professional service. The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Always seek the advice of your doctor or other qualified health provider regarding any medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. If you think you may have a medical emergency, call 9-1-1 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. JCS/T2D and any contributors, make no representations, express or implied, with respect to the information provided herein or to its use.

Conflicts of Interest

We have no commercial or financial relationships that could be construed as actual or potential conflicts of interest.

Articles

  • Dexcom's Stelo: A New Era for Type 2 Diabetes Management
  • FDA's Ongoing Evaluation of GLP-1 RAs: No Clear Link Found Between Medication and Suicidal Thoughts or Actions
  • Walking Your Way to Better Blood Sugar Control
  • Mounjaro Shortage: A Challenge for Diabetes and Obesity Patients
  • Diabetes and Eye Health
  • Exploring the Potential of Tirzepatide for Obstructive Sleep Apnea: A New Horizon in Treatment
  • Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
  • Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
  • How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
  • Addressing Misconceptions: A Closer Look at Weight Loss Drugs and Their Role in Managing Obesity and Type 2 Diabetes
  • The Dual Roles of GLP-1 and GLP-2 in Metabolic Health
  • A New Era in Diabetes Management: Once-Weekly Insulin Icodec
  • Semaglutide's Breakthrough in Kidney Disease Management
  • Innovative Weight Loss Medication Shows Promise in Lowering Blood Pressure
  • Inequality in Clinical Trials for Diabetes Treatments: A Closer Look
  • Navigating Prior Authorization for Type 2 Diabetes Treatments
  • Why I Took Medical Courses to Strengthen My Data Skills
  • The Mounjaro Supply Challenges: Looking Back and Looking Forward
  • The Economic Impact of Ozempic on Denmark
  • Understanding Obesity: Beyond the Scale

News

October 2025

  • FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
  • Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
  • Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
  • Semaglutide’s Heart Benefits Extend Beyond Weight Loss
  • Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

  • CVS Caremark Faces Lawsuit Over Dropping Zepbound
  • Dexcom Introduces Smart Basal at EASD 2025
  • Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
  • Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
  • Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
  • Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
  • Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

  • FDA Approves Wegovy for MASH Treatment
  • FDA Expands Repatha Access to More High-Risk Adults
  • Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
  • Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
  • Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
  • Signos Press Release Raises Questions About FDA Clearance Claims
  • Teva Launches First Generic GLP-1 for Obesity
  • Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

  • Type 2 Diabetes
  • Novo Nordisk
  • Semaglutide
  • Obesity Treatment
  • GLP-1
  • Wegovy
  • Eli Lilly
  • Tirzepatide
  • Ozempic
  • Zepbound
  • Diabetes
  • Obesity
  • FDA Approval
  • Diabetes Management
  • Cardiovascular Health
  • Mounjaro
  • SELECT Trial
  • Continuous Glucose Monitoring
  • GLP-1 Therapy
  • Obesity Management
  • Metabolic Health
  • Orforglipron
  • Disease Modification
  • Dexcom
  • CGM
  • Rybelsus
  • Clinical Trials
  • Oral Semaglutide
  • FDA
  • Diabetes Treatment

Contact Us

Search

5K@ADA

5K@EASD

World Obesity Day

Rochen Web Hosting

Bluesky Social

  • You are here:  
  • Home
  • Disclaimer
  • Disclaimer
 
Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.